BioLife Solutions (BLFS) director awarded 8,170 restricted shares

Rhea-AI Filing Summary

Coste Catherine reported acquisition or exercise transactions in this Form 4 filing.

BioLife Solutions director Catherine Coste reported an equity award of 8,170 shares of common stock as a grant under the BioLife Solutions 2023 Performance Incentive Plan. The restricted stock was granted at no cash price and will fully vest on the first anniversary of the vesting date of January 2, 2026. Following this award, Coste beneficially owns 13,871 common shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Coste Catherine

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	8,170	$0.00	--

Holdings After Transaction: Common Stock — 13,871 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coste Catherine

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		A		8,170	A	(1)	13,871	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan and fully vests on the first anniversary of the vesting date of January 2, 2026.

Remarks:

	/s/ Catherine Coste	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioLife Solutions (BLFS) disclose for Catherine Coste?

BioLife Solutions disclosed that director Catherine Coste received a grant of 8,170 shares of restricted common stock. The award was made at no cash price under the company’s 2023 Performance Incentive Plan, increasing her direct holdings to a total of 13,871 common shares.

How many BioLife Solutions (BLFS) shares did Catherine Coste receive and at what price?

Catherine Coste received 8,170 shares of BioLife Solutions common stock as an equity grant. The reported transaction price per share was $0.0000, reflecting a stock-based award rather than an open-market purchase, under the company’s 2023 Performance Incentive Plan.

What is the vesting schedule for Catherine Coste’s restricted stock in BioLife Solutions (BLFS)?

The restricted stock granted to Catherine Coste will fully vest on the first anniversary of the vesting date of January 2, 2026. This means the entire 8,170-share award becomes fully vested after that one-year period, subject to the plan’s terms.

What is Catherine Coste’s total BioLife Solutions (BLFS) share ownership after this grant?

After the restricted stock grant, Catherine Coste directly owns 13,871 shares of BioLife Solutions common stock. This total reflects her holdings immediately following the award of 8,170 restricted shares reported in the Form 4 insider transaction filing.

Under which equity plan was Catherine Coste’s BioLife Solutions (BLFS) stock grant made?

Catherine Coste’s restricted stock grant was made under the BioLife Solutions 2023 Performance Incentive Plan. This plan is used by the company to issue equity-based compensation, including restricted stock awards, to directors and other eligible participants.